Shares of Tilray Brands (NASDAQ: TLRY) are down 26.9% this week as of Thursday’s close, according to data provided by S&P Global Market Intelligence, after the cannabis lifestyle and consumer packaged goods specialist announced mixed quarterly results and reduced its full-year outlook.
Tilray’s growth was driven by acquisitions
For its fiscal third quarter ended Feb. 29, Tilray’s revenue grew 30% year over year to $188.3 million, falling just short of consensus estimates for $198.3 million. On the bottom line, that translated to breakeven non-GAAP (adjusted) earnings, above estimates for an adjusted $0.05-per-share net loss.
Note Tilray’s top-line growth was driven almost entirely by acquisitions. Beverage-alcohol segment revenue nearly tripled year over year to $54.7 million, thanks largely to its acquisitions of several big beer brands from AB InBev late last year. Cannabis segment sales jumped 33% year over year to $63.4 million, helped by Tilray’s takeovers of Canadian cannabis peers HEXO and Truss last year. That growth was partially offset by a 13% decline in distribution revenue, to $56.8 million, due to a combination of changing regulations surrounding rebates as well as weather and IT infrastructure outages.
“Over the past several years, our playbook of expanding our cannabis business to complementary markets such as beverages and hemp-based consumer products has positioned us well to navigate the current environment and to benefit from future growth opportunities,” Tilray chairman and CEO Irwin Simon said.
Why Tilray lowered its outlook
Perhaps more concerning to Wall Street was Tilray’s reduced outlook for the full fiscal year ending May 31, 2024. Tilray now sees adjusted earnings before interest, taxes, depreciaition, and amortization (EBITDA) of $60 million to $63 million (versus previous guidance for $68 million to $78 million), and management no longer expects to achieve positive free cash flow this year as previously anticipated. On the latter, however, Tilray primarily blamed the impact of delayed timing for collecting cash on various asset sales — so investors can take solace knowing it’s not reflective of a fundamental negative change in Tilray’s underlying profitability or cash-flow-generating capabilities.
In any case, I think Tilray’s long-term thesis remains intact, particularly given the mid-term prospect of cannabis legalization on a federal level in the United States (where Tilray currently generates no revenue from cannabis operations). Keeping in mind shares rallied nearly 80% in the four weeks leading up to this week’s earnings release, I think this pullback isn’t as severe as it seems at first glance. And I believe long-term investors would do well to stay the course.
Should you invest $1,000 in Tilray Brands right now?
Before you buy stock in Tilray Brands, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tilray Brands wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of April 8, 2024
Steve Symington has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy.
Why Tilray Brands Stock Fell 26.9% This Week was originally published by The Motley Fool
Signup bonus from
